Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:ACSF2-ABCA9

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: ACSF2-ABCA9
	FusionPDB ID: 1482
	FusionGDB2.0 ID: 1482
		Hgene	Tgene
	Gene symbol	ACSF2	ABCA9
	Gene ID	80221	10350
	Gene name	acyl-CoA synthetase family member 2	ATP binding cassette subfamily A member 9
	Synonyms	ACSMW\|AVYV493	EST640918
	Cytomap	17q21.33	17q24.2
	Type of gene	protein-coding	protein-coding
	Description	medium-chain acyl-CoA ligase ACSF2, mitochondrialPPARG binding, long chain fatty acid acyl Co-A ligase likeacyl-CoA synthetase family member 2, mitochondrial	ATP-binding cassette sub-family A member 9ATP-binding cassette A9ATP-binding cassette, sub-family A (ABC1), member 9
	Modification date	20200313	20200313
	UniProtAcc	Q96CM8 Main function of 5'-partner protein: FUNCTION: Acyl-CoA synthases catalyze the initial reaction in fatty acid metabolism, by forming a thioester with CoA (PubMed:17762044). Has some preference toward medium-chain substrates (PubMed:17762044). Plays a role in adipocyte differentiation (PubMed:16380219). {ECO:0000269\|PubMed:16380219, ECO:0000269\|PubMed:17762044}.	Q8IUA7 Main function of 5'-partner protein: FUNCTION: Transporter that may play a role in monocyte differentiation and lipid transport and homeostasis. {ECO:0000305\|PubMed:12150964}.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000300441, ENST00000427954, ENST00000502667, ENST00000504392, ENST00000541920, ENST00000506085,	ENST00000482072, ENST00000495634, ENST00000340001, ENST00000370732, ENST00000453985,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	6 X 4 X 4=96	6 X 5 X 4=120
	# samples	6	6
	** MAII score	log2(6/96*10)=-0.678071905112638 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(6/120*10)=-1 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: ACSF2 [Title/Abstract] AND ABCA9 [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: ACSF2 [Title/Abstract] AND ABCA9 [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	ACSF2(48503750)-ABCA9(67020494), # samples:2
Anticipated loss of major functional domain due to fusion event.	ACSF2-ABCA9 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. ACSF2-ABCA9 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. ACSF2-ABCA9 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. ACSF2-ABCA9 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner

Gene

GO ID

GO term

PubMed ID

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr17:48503750/chr17:67020494)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across ACSF2 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across ABCA9 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000300441	ACSF2	chr17	48503750	+	ENST00000340001	ABCA9	chr17	67020494	-	4393	232	35	2965	976
ENST00000300441	ACSF2	chr17	48503750	+	ENST00000453985	ABCA9	chr17	67020494	-	4135	232	35	2851	938
ENST00000300441	ACSF2	chr17	48503750	+	ENST00000370732	ABCA9	chr17	67020494	-	4153	232	35	2398	787
ENST00000504392	ACSF2	chr17	48503750	+	ENST00000340001	ABCA9	chr17	67020494	-	4333	172	44	2905	953
ENST00000504392	ACSF2	chr17	48503750	+	ENST00000453985	ABCA9	chr17	67020494	-	4075	172	44	2791	915
ENST00000504392	ACSF2	chr17	48503750	+	ENST00000370732	ABCA9	chr17	67020494	-	4093	172	44	2338	764
ENST00000427954	ACSF2	chr17	48503750	+	ENST00000340001	ABCA9	chr17	67020494	-	4332	171	43	2904	953
ENST00000427954	ACSF2	chr17	48503750	+	ENST00000453985	ABCA9	chr17	67020494	-	4074	171	43	2790	915
ENST00000427954	ACSF2	chr17	48503750	+	ENST00000370732	ABCA9	chr17	67020494	-	4092	171	43	2337	764
ENST00000502667	ACSF2	chr17	48503750	+	ENST00000340001	ABCA9	chr17	67020494	-	4299	138	10	2871	953
ENST00000502667	ACSF2	chr17	48503750	+	ENST00000453985	ABCA9	chr17	67020494	-	4041	138	10	2757	915
ENST00000502667	ACSF2	chr17	48503750	+	ENST00000370732	ABCA9	chr17	67020494	-	4059	138	10	2304	764

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000300441	ENST00000340001	ACSF2	chr17	48503750	+	ABCA9	chr17	67020494	-	0.00030478	0.9996953
ENST00000300441	ENST00000453985	ACSF2	chr17	48503750	+	ABCA9	chr17	67020494	-	0.000442166	0.9995578
ENST00000300441	ENST00000370732	ACSF2	chr17	48503750	+	ABCA9	chr17	67020494	-	0.000948241	0.99905175
ENST00000504392	ENST00000340001	ACSF2	chr17	48503750	+	ABCA9	chr17	67020494	-	0.000290058	0.9997099
ENST00000504392	ENST00000453985	ACSF2	chr17	48503750	+	ABCA9	chr17	67020494	-	0.000427705	0.99957234
ENST00000504392	ENST00000370732	ACSF2	chr17	48503750	+	ABCA9	chr17	67020494	-	0.00090572	0.99909425
ENST00000427954	ENST00000340001	ACSF2	chr17	48503750	+	ABCA9	chr17	67020494	-	0.000288858	0.9997111
ENST00000427954	ENST00000453985	ACSF2	chr17	48503750	+	ABCA9	chr17	67020494	-	0.00042567	0.99957436
ENST00000427954	ENST00000370732	ACSF2	chr17	48503750	+	ABCA9	chr17	67020494	-	0.000901836	0.9990982
ENST00000502667	ENST00000340001	ACSF2	chr17	48503750	+	ABCA9	chr17	67020494	-	0.000301635	0.9996984
ENST00000502667	ENST00000453985	ACSF2	chr17	48503750	+	ABCA9	chr17	67020494	-	0.000446508	0.9995535
ENST00000502667	ENST00000370732	ACSF2	chr17	48503750	+	ABCA9	chr17	67020494	-	0.00094341	0.99905664

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for ACSF2-ABCA9

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
ACSF2	chr17	48503750	ABCA9	chr17	67020494	138	42	SWQEARLQGVRFLSLHLNERCDPESI
ACSF2	chr17	48503750	ABCA9	chr17	67020494	171	42	SWQEARLQGVRFLSLHLNERCDPESI
ACSF2	chr17	48503750	ABCA9	chr17	67020494	172	42	SWQEARLQGVRFLSLHLNERCDPESI
ACSF2	chr17	48503750	ABCA9	chr17	67020494	232	65	SWQEARLQGVRFLSLHLNERCDPESI

Top

Potential FusionNeoAntigen Information of ACSF2-ABCA9 in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

ACSF2-ABCA9_48503750_67020494.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
ACSF2-ABCA9	chr17	48503750	chr17	67020494	232	HLA-B27:04	VRFLSLHL	1	0.8022	9	17
ACSF2-ABCA9	chr17	48503750	chr17	67020494	232	HLA-B14:02	VRFLSLHL	0.9987	0.6623	9	17
ACSF2-ABCA9	chr17	48503750	chr17	67020494	232	HLA-B14:01	VRFLSLHL	0.9987	0.6623	9	17
ACSF2-ABCA9	chr17	48503750	chr17	67020494	232	HLA-B08:01	LQGVRFLSL	0.9912	0.6324	6	15
ACSF2-ABCA9	chr17	48503750	chr17	67020494	232	HLA-B14:02	LQGVRFLSL	0.9909	0.6504	6	15
ACSF2-ABCA9	chr17	48503750	chr17	67020494	232	HLA-B14:01	LQGVRFLSL	0.9909	0.6504	6	15
ACSF2-ABCA9	chr17	48503750	chr17	67020494	232	HLA-B08:09	LQGVRFLSL	0.9802	0.6918	6	15
ACSF2-ABCA9	chr17	48503750	chr17	67020494	232	HLA-A30:08	GVRFLSLHL	0.9643	0.7261	8	17
ACSF2-ABCA9	chr17	48503750	chr17	67020494	232	HLA-A31:02	RFLSLHLNER	0.961	0.5578	10	20
ACSF2-ABCA9	chr17	48503750	chr17	67020494	232	HLA-B27:04	ARLQGVRFLSL	1	0.7831	4	15
ACSF2-ABCA9	chr17	48503750	chr17	67020494	232	HLA-B27:05	ARLQGVRFLSL	1	0.775	4	15
ACSF2-ABCA9	chr17	48503750	chr17	67020494	232	HLA-B27:07	ARLQGVRFLSL	1	0.5755	4	15
ACSF2-ABCA9	chr17	48503750	chr17	67020494	232	HLA-C07:95	VRFLSLHL	0.9997	0.7019	9	17
ACSF2-ABCA9	chr17	48503750	chr17	67020494	232	HLA-C07:05	VRFLSLHL	0.9997	0.973	9	17
ACSF2-ABCA9	chr17	48503750	chr17	67020494	232	HLA-C07:27	VRFLSLHL	0.9996	0.9575	9	17
ACSF2-ABCA9	chr17	48503750	chr17	67020494	232	HLA-B14:03	LQGVRFLSL	0.7947	0.7182	6	15
ACSF2-ABCA9	chr17	48503750	chr17	67020494	232	HLA-A31:01	RFLSLHLNER	0.9896	0.5535	10	20
ACSF2-ABCA9	chr17	48503750	chr17	67020494	232	HLA-B27:14	ARLQGVRFLSL	1	0.7681	4	15
ACSF2-ABCA9	chr17	48503750	chr17	67020494	232	HLA-B27:03	ARLQGVRFLSL	0.9995	0.8082	4	15
ACSF2-ABCA9	chr17	48503750	chr17	67020494	232	HLA-B27:06	VRFLSLHL	1	0.7692	9	17
ACSF2-ABCA9	chr17	48503750	chr17	67020494	232	HLA-B27:09	VRFLSLHL	0.9999	0.9364	9	17
ACSF2-ABCA9	chr17	48503750	chr17	67020494	232	HLA-C07:01	VRFLSLHL	0.9998	0.6326	9	17
ACSF2-ABCA9	chr17	48503750	chr17	67020494	232	HLA-C06:08	VRFLSLHL	0.9957	0.9946	9	17
ACSF2-ABCA9	chr17	48503750	chr17	67020494	232	HLA-C06:17	VRFLSLHL	0.9176	0.9956	9	17
ACSF2-ABCA9	chr17	48503750	chr17	67020494	232	HLA-C06:02	VRFLSLHL	0.9176	0.9956	9	17
ACSF2-ABCA9	chr17	48503750	chr17	67020494	232	HLA-B08:18	LQGVRFLSL	0.9912	0.6324	6	15
ACSF2-ABCA9	chr17	48503750	chr17	67020494	232	HLA-A30:01	GVRFLSLHL	0.9691	0.8866	8	17
ACSF2-ABCA9	chr17	48503750	chr17	67020494	232	HLA-B08:12	LQGVRFLSL	0.9213	0.7306	6	15
ACSF2-ABCA9	chr17	48503750	chr17	67020494	232	HLA-B15:73	LQGVRFLSL	0.8369	0.78	6	15
ACSF2-ABCA9	chr17	48503750	chr17	67020494	232	HLA-B27:06	ARLQGVRFLSL	1	0.7817	4	15
ACSF2-ABCA9	chr17	48503750	chr17	67020494	232	HLA-B27:09	ARLQGVRFLSL	1	0.7808	4	15
ACSF2-ABCA9	chr17	48503750	chr17	67020494	232	HLA-B27:10	ARLQGVRFLSL	1	0.8758	4	15
ACSF2-ABCA9	chr17	48503750	chr17	67020494	232	HLA-B27:08	ARLQGVRFLSL	1	0.6571	4	15

Top

Potential FusionNeoAntigen Information of ACSF2-ABCA9 in HLA II

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene

Hchr

Hbp

Tgene

Tchr

Tbp

HLA II

FusionNeoAntigen peptide

Neoantigen start (at BP 13)

Neoantigen end (at BP 13)

Top

Fusion breakpoint peptide structures of ACSF2-ABCA9

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
5451	LQGVRFLSLHLNER	ACSF2	ABCA9	chr17	48503750	chr17	67020494	232

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of ACSF2-ABCA9

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	5451	LQGVRFLSLHLNER	-7.9962	-8.1096
HLA-B14:02	3BVN	5451	LQGVRFLSLHLNER	-5.70842	-6.74372
HLA-B52:01	3W39	5451	LQGVRFLSLHLNER	-6.83737	-6.95077
HLA-B52:01	3W39	5451	LQGVRFLSLHLNER	-4.4836	-5.5189
HLA-A11:01	4UQ2	5451	LQGVRFLSLHLNER	-10.0067	-10.1201
HLA-A11:01	4UQ2	5451	LQGVRFLSLHLNER	-9.03915	-10.0745
HLA-A24:02	5HGA	5451	LQGVRFLSLHLNER	-6.56204	-6.67544
HLA-A24:02	5HGA	5451	LQGVRFLSLHLNER	-5.42271	-6.45801
HLA-B44:05	3DX8	5451	LQGVRFLSLHLNER	-7.85648	-8.89178
HLA-B44:05	3DX8	5451	LQGVRFLSLHLNER	-5.3978	-5.5112
HLA-A02:01	6TDR	5451	LQGVRFLSLHLNER	-3.37154	-4.40684

Top

Vaccine Design for the FusionNeoAntigens of ACSF2-ABCA9

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
ACSF2-ABCA9	chr17	48503750	chr17	67020494	10	20	RFLSLHLNER	CTTCCTCAGTTTGCATCTGAATGAAAGGTG
ACSF2-ABCA9	chr17	48503750	chr17	67020494	4	15	ARLQGVRFLSL	CAGGTTGCAGGGTGTCCGCTTCCTCAGTTTGCA
ACSF2-ABCA9	chr17	48503750	chr17	67020494	6	15	LQGVRFLSL	GCAGGGTGTCCGCTTCCTCAGTTTGCA
ACSF2-ABCA9	chr17	48503750	chr17	67020494	8	17	GVRFLSLHL	TGTCCGCTTCCTCAGTTTGCATCTGAA
ACSF2-ABCA9	chr17	48503750	chr17	67020494	9	17	VRFLSLHL	CCGCTTCCTCAGTTTGCATCTGAA

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene

Hchr

Hbp

Tchr

Tbp

Start in +/-13AA

End in +/-13AA

FusionNeoAntigen peptide

FusionNEoAntigen RNA sequence

Top

Information of the samples that have these potential fusion neoantigens of ACSF2-ABCA9

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
SKCM	ACSF2-ABCA9	chr17	48503750	ENST00000300441	chr17	67020494	ENST00000340001	TCGA-ER-A197-06A

Top

Potential target of CAR-T therapy development for ACSF2-ABCA9

Predicted 3D structure. We used RoseTTAFold.

10_ACSF2-ABCA9_t000_.e2e.pdb

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Tgene

ABCA9

chr17:48503750

chr17:67020494

ENST00000340001

1026_1046

1625.0

Transmembrane

Helical

Tgene

ABCA9

chr17:48503750

chr17:67020494

ENST00000340001

1065_1085

1625.0

Transmembrane

Helical

Tgene

ABCA9

chr17:48503750

chr17:67020494

ENST00000340001

1108_1128

1625.0

Transmembrane

Helical

Tgene

ABCA9

chr17:48503750

chr17:67020494

ENST00000340001

1136_1156

1625.0

Transmembrane

Helical

Tgene

ABCA9

chr17:48503750

chr17:67020494

ENST00000340001

1163_1183

1625.0

Transmembrane

Helical

Tgene

ABCA9

chr17:48503750

chr17:67020494

ENST00000340001

1200_1220

1625.0

Transmembrane

Helical

Tgene

ABCA9

chr17:48503750

chr17:67020494

ENST00000340001

864_884

1625.0

Transmembrane

Helical

Tgene

ABCA9

chr17:48503750

chr17:67020494

ENST00000370732

1026_1046

1790.0

Transmembrane

Helical

Tgene

ABCA9

chr17:48503750

chr17:67020494

ENST00000370732

1065_1085

1790.0

Transmembrane

Helical

Tgene

ABCA9

chr17:48503750

chr17:67020494

ENST00000370732

1108_1128

1790.0

Transmembrane

Helical

Tgene

ABCA9

chr17:48503750

chr17:67020494

ENST00000370732

1136_1156

1790.0

Transmembrane

Helical

Tgene

ABCA9

chr17:48503750

chr17:67020494

ENST00000370732

1163_1183

1790.0

Transmembrane

Helical

Tgene

ABCA9

chr17:48503750

chr17:67020494

ENST00000370732

1200_1220

1790.0

Transmembrane

Helical

Tgene

ABCA9

chr17:48503750

chr17:67020494

ENST00000370732

864_884

1790.0

Transmembrane

Helical

Tgene

ABCA9

chr17:48503750

chr17:67020494

ENST00000495634

1026_1046

268.0

Transmembrane

Helical

Tgene

ABCA9

chr17:48503750

chr17:67020494

ENST00000495634

1065_1085

268.0

Transmembrane

Helical

Tgene

ABCA9

chr17:48503750

chr17:67020494

ENST00000495634

1108_1128

268.0

Transmembrane

Helical

Tgene

ABCA9

chr17:48503750

chr17:67020494

ENST00000495634

1136_1156

268.0

Transmembrane

Helical

Tgene

ABCA9

chr17:48503750

chr17:67020494

ENST00000495634

1163_1183

268.0

Transmembrane

Helical

Tgene

ABCA9

chr17:48503750

chr17:67020494

ENST00000495634

1200_1220

268.0

Transmembrane

Helical

Tgene

ABCA9

chr17:48503750

chr17:67020494

ENST00000495634

221_243

268.0

Transmembrane

Helical

Tgene

ABCA9

chr17:48503750

chr17:67020494

ENST00000495634

269_289

268.0

Transmembrane

Helical

Tgene

ABCA9

chr17:48503750

chr17:67020494

ENST00000495634

300_320

268.0

Transmembrane

Helical

Tgene

ABCA9

chr17:48503750

chr17:67020494

ENST00000495634

31_51

268.0

Transmembrane

Helical

Tgene

ABCA9

chr17:48503750

chr17:67020494

ENST00000495634

329_349

268.0

Transmembrane

Helical

Tgene

ABCA9

chr17:48503750

chr17:67020494

ENST00000495634

354_374

268.0

Transmembrane

Helical

Tgene

ABCA9

chr17:48503750

chr17:67020494

ENST00000495634

398_418

268.0

Transmembrane

Helical

Tgene

ABCA9

chr17:48503750

chr17:67020494

ENST00000495634

864_884

268.0

Transmembrane

Helical

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene	Hchr	Hbp	Henst	Tgene	Tchr	Tbp	Tenst	DeepLoc result
ACSF2	chr17	48503750	ENST00000300441	ABCA9	chr17	67020494	ENST00000340001
ACSF2	chr17	48503750	ENST00000300441	ABCA9	chr17	67020494	ENST00000370732
ACSF2	chr17	48503750	ENST00000300441	ABCA9	chr17	67020494	ENST00000453985
ACSF2	chr17	48503750	ENST00000427954	ABCA9	chr17	67020494	ENST00000340001
ACSF2	chr17	48503750	ENST00000427954	ABCA9	chr17	67020494	ENST00000370732
ACSF2	chr17	48503750	ENST00000427954	ABCA9	chr17	67020494	ENST00000453985

Top

Related Drugs to ACSF2-ABCA9

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to ACSF2-ABCA9

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)